Weight-loss medications reduced body weight in children and teens, but the sample size was too small to make conclusions ...

A new large-scale study came to the conclusion that weight-loss surgery gives people with type 2 diabetes and obesity a ...

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

An experimental GLP-1 pill called orforglipron promoted substantial weight loss without the need for weekly injections, ...

The once-daily oral GLP-1 RA orforglipron produces clinically and statistically significant weight loss and cardiometabolic ...

This is the first completed phase III trial of an oral, small-molecule GLP-1 receptor agonist in people with obesity, Wharton ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and ...

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.

The rollout of antiretroviral therapy for HIV showed how global solidarity and smart policy can overcome barriers to new ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the ...

Dublin, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The "Japan Auto-Injectors for Glp-1 Receptor Agonists Market Outlook 2038" report has been added to ResearchAndMarkets.com's offering. Japan auto-injectors ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.